{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:20:23Z","timestamp":1791829223247,"version":"4.3.4"},"reference-count":7,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clinthera.2021.04.014","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T07:02:24Z","timestamp":1622962944000},"page":"1029-1050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants"],"prefix":"10.1016","volume":"43","author":[{"given":"LuAnn","family":"Bundrant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Gopinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi A.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kassler-Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Tyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Wason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.04.014_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.neuro.051508.135531","article-title":"Neuropathic pain: a maladaptive response of the nervous system to damage","volume":"32","author":"Costigan","year":"2009","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.clinthera.2021.04.014_bib0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pain.2010.06.019","article-title":"The evidence for pharmacological treatment of neuropathic pain","volume":"150","author":"Finnerup","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2021.04.014_bib0003","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/ijcp.12411","article-title":"Systemic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions","volume":"68","author":"Snedecor","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2021.04.014_bib0004","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1124\/jpet.116.235333","article-title":"Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain","volume":"358","author":"Kostich","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2021.04.014_bib0005","first-page":"1013","article-title":"LX9211 A Selective Inhibitor of AAK1 (Adapter-Associated Kinase) for Neuropathic Pain? Some Thoughts on Selectivity and Specificity","volume":"3","author":"Hesselink","year":"2018","journal-title":"Austin Neurol"},{"key":"10.1016\/j.clinthera.2021.04.014_bib0006","unstructured":"Lou G., Chen L., Dzierba C.D., et\u00a0al. United States Patent No. US 9,902,722 B2."},{"key":"10.1016\/j.clinthera.2021.04.014_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9353940","article-title":"Evaluation of Treatment Patterns and Direct Costs Associated with the Management of Neuropathic Pain","volume":"2020","author":"Machado-Duque","year":"2020","journal-title":"Pain Research Manage"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:51Z","timestamp":1758963291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0149291821002095"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}